Zobrazeno 1 - 10
of 47
pro vyhledávání: '"Phillip J. Yates"'
Autor:
Phillip J Yates, Jennifer Moore, Jennifer Han, Andrew Skingsley, Gretja Schnell, Andrea L Cathcart, Melissa Aldinger, Amanda Peppercorn, Jill Walker
Publikováno v:
Open Forum Infectious Diseases. 9
Background Sotrovimab is a human monoclonal antibody targeting a conserved region of the SARS-CoV-2 spike (S) protein. COMET-PEAK was a 3-part, phase 2 study that evaluated intravenous (500 mg) and intramuscular (500 mg and 250 mg) administration of
Autor:
Yvonne Tami, Shihyun You, Melanie Paff, Jeong-Won Jang, Robert Elston, Sung-Jae Park, Phillip J. Yates, Yu Tao, Jung Hwan Yoon, C. Frank Bennett, Jennifer Cremer, Jeong Heo, Dickens Theodore, T. Jesse Kwoh, Man-Fung Yuen, Young-Oh Kweon, Fiona Campbell
Publikováno v:
Nature Medicine
Cell Reports Medicine
Cell Reports Medicine
Chronic infection with hepatitis B virus (HBV) leads to an increased risk of death from cirrhosis and hepatocellular carcinoma. Functional cure rates are low with current treatment options (nucleos(t)ide analogs (NAs) and pegylated interferons). Bepi
Publikováno v:
Virus Research. 325:199039
Influenza infection causes substantial morbidity and mortality during seasonal epidemics and pandemics. Antivirals, including neuraminidase inhibitors, play an important role in the treatment of severely ill patients infected with influenza. Resistan
Autor:
Phillip J. Yates, Malek Okour, Jon Collins, Grace Roberts, Peiying Zuo, Helen A. Watson, Denise Shortino, Aline Barth, Mohammad Hossain, Amanda Peppercorn
Publikováno v:
Clinical and Translational Science, Vol 13, Iss 1, Pp 157-168 (2020)
Clinical and Translational Science
Clinical and Translational Science
Zanamivir is a potent and highly selective inhibitor of influenza neuraminidase in which the inhibition of this enzyme prevents the virus from infecting other cells and specifically prevents release of the new virion from the host cell membrane. It i
Autor:
Phillip J. Yates, Sumita Roy-Ghanta, G B Roberts, Michael L Washburn, Andrew J. Peat, Michael F. Parry, Yu Tao, Anuradha Madan, Shuguang Chen, Otis Barnum, Micah T. McClain
Publikováno v:
Open Forum Infectious Diseases
Background Excessive neutrophil migration has been correlated with influenza symptom severity. Danirixin (GSK1325756), a selective and reversible antagonist of C-X-C chemokine receptor 2, decreases neutrophil activation and transmigration to areas of
Autor:
Jill Walker, Michael L Washburn, Sumita Roy-Ghanta, Phillip J. Yates, Andrew J. Peat, Edward Kerwin, Gary Soucie, G B Roberts, Anuradha Madan, Shuguang Chen
Publikováno v:
Open Forum Infectious Diseases
Background Danirixin (DNX), a selective and reversible CXC chemokine receptor 2 antagonist, inhibits neutrophil transmigration and activation. This study assessed the safety, tolerability, and clinical effect of DNX with and without oseltamivir (OSV)
Autor:
Jonathan P. O'Doherty, Pat Cain, Abigail Johnson, Phillip J. Yates, James Harding, Karl A. Holden
Publikováno v:
Annals of Vascular Surgery. 62:498.e15-498.e17
Background Central venous stenosis and occlusion (CVO) is an increasing problem in the growing hemodialysis population. Sequelae include loss of access, loss of sites suitable for future venous access, and venous hypertension. Endoluminal techniques
Autor:
Phillip J Yates, Abheesh R. Prasad, Dominic Heining, Andrew Bentall, Jonathan Senior, Michael Thomas
Publikováno v:
Oxford Medical Case Reports. 2018
We present a case of angiosarcoma at an arteriovenous fistula site in a non-immunocompromised patient presenting as a soft tissue swelling with associated findings suggestive of lung malignancy, metastases and bleeding diathesis. This patient died of
Autor:
Jose R. Romero, John S. Bradley, Bryan E. Adams, Roberta L. DeBiasi, Jeffrey L. Blumer, Denise Shortino, Phillip J. Yates, Marian G. Michaels, Go Yamamoto, Amanda Peppercorn, David W. Kimberlin, Barbara A. Pahud, Flor M. Munoz, G B Roberts, Mohammad Hossain
Publikováno v:
Pediatrics. 140(5)
BACKGROUND: Children with severe influenza infection may require parenteral therapy if oral or inhaled therapies are ineffective or cannot be administered. Results from a study investigating intravenous (IV) zanamivir for the treatment of hospitalize
Autor:
Helen A. Watson, Francisco M. Marty, Denise D Shortino, Sandeep Kumar Gupta, Joan Vidal-Puigserver, Petr Husa, Frédérique Jacobs, Esperanza Merino, Phillip J. Yates, Eduardo Rodríguez-Noriega, Marianne J. Chapman, Carol L. Clark, Amanda Peppercorn, Denis Garot
Publikováno v:
LANCET RESPIRATORY MEDICINE
r-FISABIO. Repositorio Institucional de Producción Científica
instname
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
r-FISABIO. Repositorio Institucional de Producción Científica
instname
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Background Neuraminidase inhibitors are effective for the treatment of acute uncomplicated influenza. However, there is an unmet need for intravenous treatment for patients admitted to hospital with severe influenza. We studied whether intravenous za
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54242041af18874e7fa5c85733d1ddae
https://fundanet.fisabio.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=1884
https://fundanet.fisabio.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=1884